Avtor/Urednik		Dernič, Jani
Naslov		Zunajbolnišnična pljučnica - sodobni pogledi in lastne izkušnje
Prevedeni naslov		Community - acquired pneumonia - current concepts and our own experience
Tip		članek
Vir		Krka Med Farm Supl
Vol. in št.		Letnik 20, št. Suppl 2
Leto izdaje		1999
Obseg		str. 25-35
Jezik		slo
Abstrakt		Eighty-seven out patients with community acquired pneumonia were included in a prospective, noncomparative, multicentre, clinical trial conducted in Slovenia. lncluded were female and male patients aged 18 to 65 (average age 44.6 +- 14.3). Thirty percent of the patients were smokers and 25% of them presented with accompanying diseases. The clinical diagnosis of community-acquired pneumonia was confirmed by x-ray examination. The efficacy evaluation was based on clinical symptoms and laboratory findings, including CRP. The patients were treated with clarithromycin (Fromilid) in doses of 500 mg administered every 12 hours. The efficacy of the treatment was evaluated at the end of the treatment period of on average duration of 11.7 +- 2.7 days. The treatment was assessed as successful in 97% of the patients (cure of improvement). The most frequently experienced edverse reactions included mild and transient gastrointestinal symptoms (16% of the patients). Three patients discontinued treatment due to adverse reactions of moderate severity. Empirical treatment with clarithromycin proved highly effective in the management of community-acquired pneumonia of milder severity in adults and was associated with an acceptable incidence of adverse reactions.
Izvleček		V prospektivni neprimerjalni multicentrični klinični raziskavi v Sloveniji smo zaradi zunajbolnišnične pljučnice ambulantno zdravili 87 bolnikov. V raziskavo smo vključili bolnice in bolnike, stare od 18 do 65 let, povprečna starost je bila 44,6 +- 14,3 leta. Med vključenimi je bilo 30 % kadilcev, 25 % pa jih je imelo sočasno še druge bolezni. Diagnoza je bila postavljena klinično in potrjena z rentgensko sliko. Spremljali smo klinično simptomatiko ter laboratorijske vrednosti, vključno s CRP. Bolniki so na vsakih 12 ur prejeli 500 mg klaritromicina (Fromilida). Po končanem zdravljenju, ki je trajalo povprečno 11,7 +- 2,7 dneva, smo ocenili uspešnost zdravljenja. To je bilo uspešno pri 97 % bolnikov (ozdravitev in izboljšanje). Stranski učinki, najpogosteje so bili to blažje in prehodne prebavne motnje, so se pojavile pri 16 % bolnikov. Trije bolniki zaradi stranskih učinkov, ki so bili ocenjeni kot zmerni, zdravljenja niso končali. Empirično zdravljenje lažjih zunajbolnišničnih pljučnic pri odraslih s klaritromicinom je bilo zelo uspešno, število stranskih učinkov pa sprejemljivo.
Deskriptorji		PNEUMONIA COMMUNITY-ACQUIRED INFECTIONS AMBULATORY CARE FEVER COUGH DYSPNEA CHEST PAIN THORACIC RADIOGRAPHY TREATMENT OUTCOME